



**World  
Urological  
Oncology  
Federation**

**New Technologies  
and New Therapies in  
Urologic Oncology**

### **6th Annual WUOF Conference**

Fukuoka International Congress Center,  
Fukuoka, Japan

**Scientific Program Chair** | Tsuneharu Miki, MD, Kyoto, Japan

**Sunday September 30 | Room 201**

### **WELCOME & INTRODUCTIONS**

0800 **Chairman's Welcome** | Laurence Klotz, MD | Canada  
0805 **Opening Remarks** | Yukio Homma, MD | Japan

#### **0810 SESSION ONE | CAN-ASIA-PACIFIC PERSPECTIVES IN KIDNEY CANCER**

**Co-Moderator** | Yoshihiko Tomita, MD | Japan  
**Co-Moderator** | Michael Jewett, MD | Canada

0815 **Update on the Management of Small Renal Masses** | Michael Jewett, MD | Canada  
0830 **Renal Cell Carcinoma: Stage Migration and Changing Patterns of Treatment in Australia**  
| Manish Patel, MBBS PhD | Australia

0845 **Locally Advanced Kidney Cancer: Role of Neoadjuvant Therapy** | Jinsoo Chung | Korea  
0900 **Focal Therapy with RFA for Renal Cell Carcinoma** | Fumiya Hongo, MD | Japan  
0915 **Environmental & Modifiable Risk Factors in Renal Cell Carcinoma** | Christopher Wood, MD | USA

#### **0945 SESSION TWO | BLADDER CANCER**

**Co-Moderator** | Antonio Pompeo, MD | Brazil  
**Co-Moderator** | Masayuki Nakagawa, MD | Japan

0950 **Photodynamic Diagnosis and Treatment for Bladder Cancer** | Keiji Inoue, MD | Japan  
1005 **New Treatments in the Management of Non-Muscle Invasive Disease** | Maurizio Brausi, MD | Italy  
1020 **Chinese Perspective on the Management of Invasive Bladder Cancer** | Ningchen Li, MD | China  
1030 **Changing Patterns of Bladder Cancer in Egypt** | Hassan Abol-Enein, MD | Egypt

#### **DISCUSSION**

#### **1100 BLADDER CANCER DEBATE | Management of High Grade T1 TCC**

1100 **Most Patients with High Grade T1 Should be Treated Initially with Intravesical Therapy**  
| George Thalmann, MD | Switzerland

1110 **Most Patients with High Grade T1 Should be Treated with Primary Cystectomy**  
| Joseph Chin, MD | Canada

#### **DISCUSSION**

#### **1130 BREAK**

#### **1145 SESSION THREE | ADVANCED DISEASE PROSTATE CANCER**

**Co-Moderator** | Mark Frydenberg, MD | Australia  
**Co-Moderator** | Mototsugu Oya, MD | Japan

1150 **Role of Surgery for Locally Advanced High Risk Prostate Cancer** | Christopher Cheng, MD | Singapore  
1205 **Genetic Biomarkers in Prostate Cancer** | Robert Nam, MD | Canada  
1220 **The Clinical Role of Peptide Vaccines for CRPC - Prospective Randomized Study of Peptide Vaccination vs Steroid Hormone Alone** | Hirotsugu Uemura, MD | Japan

1235 **Role of New Androgen Receptor Targeted Therapies** | Neil Fleshner, MD | Canada

1250 **PANEL DISCUSSION** | Drs. Cheng, Nam, Uemura, Fleshner and Baskin-Bey

#### **1300 BREAK**

#### **1310 LUNCHEON SEMINAR | VACCINE THERAPY FOR MRCC**

**Introduction** | Tsuneharu Miki, WUOF Scientific Program Chair  
**A novel multi-peptide vaccine for treatment of RCC** | Harpreet Singh, PhD | Germany

**COMPLIMENTARY LUNCH PROVIDED FOR ALL REGISTRANTS**

#### **1345 SESSION FOUR | SCREENING & LOCALIZED PROSTATE CANCER**

**Co-Moderator** | Laurence Klotz, MD | Canada  
**Co-Moderator** | Norio Nonomura | Japan

1350 **Screening for Prostate Cancer** | Peter Albertsen, MD | USA

1405 **The Goteborg Trial** | Jonas Hugosson, MD | Sweden

1420 **Development of Nomograms to Predict Probability of Positive-Initial Prostate Biopsy Among Japanese Patients** | Hiroyoshi Suzuki, MD | Japan

1435 **Focal Therapy and Role of MRI** | Mark Emberton, MD | England

1450 **Focal Therapy - Patient Selection** | John Ward, MD | USA

1505 **Focal Therapy - Why is it a Bad Idea?** | Adam Kibel, MD | USA

1520 **CASE DISCUSSION** | Focal Therapy

#### **1530 ADJOURN**

#### **1700 SIU OPENING CEREMONIES | WELCOME RECEPTION**

agenda

2012 WUOF Conference  
Fukuoka Japan  
Sunday, September 30

#### **WUOF Chairman:**

Laurence Klotz, MD

#### **Steering Committee:**

Laurence Klotz

Canada

Marcello Bendhack

Brazil

Ningchen Li

China

Peter Albers

Germany

Tsuneharu Miki

Japan

Hirotsugu Uemura

Japan

Arturo Mendoza-Valdes

Mexico

Christopher Cheng

Singapore

Roger Kockelbergh

United Kingdom



SIU 2012

[www.wuof.org](http://www.wuof.org)

**PARTICIPANTS:**

**Australia**

**Mark Frydenberg**, MBBS, FRACS (Urology)  
Chairman, Uro-oncology Special Advisory Group  
Urological Society of Australia and New Zealand  
Associate Professor, Department of Surgery  
Faculty of Medicine and Health Sciences,  
Monash University  
Chairman, Department of Urology, Monash  
Medical Centre  
Chairman, Clinical Institute of Specialty Surgery,  
Epworth Healthcare  
Melbourne, Victoria, Australia

**Manish I. Patel**, MBBS, PhD  
Associate Professor  
Urological Cancer Surgeon  
University of Sydney  
Westmead and Sydney Adventist Hospitals  
Sydney, Australia

**Brazil**

**Antonio Pompeo**, MD  
Professor and Chairman - Department of  
Urology, ABC Medical School, São Paulo, Brazil  
Director of the Oncology Department, Brazilian  
Society of Urology  
Director of the Scholarships Department -  
American Confederation of Urology (CAU)  
Chairman of the Publications Committee of the  
Société Internationale d'Urologie (SIU)

**Canada**

**Joseph L. Chin**, OOnt, MD, FRCS  
Professor of Urology & Oncology  
University of Western Ontario  
London Ontario, CANADA

**Neil Fleshner**, MD, MPH, FRCS  
Head, Division of Urology,  
University Health Network  
Professor of Surgery,  
University of Toronto

**Michael Jewett**, MD  
Department of Surgical Oncology (Urology),  
Princess Margaret Hospital/University Health  
Network, Professor, Department of  
Surgery (Urology), University of Toronto

**Laurence Klotz**, MD  
Professor of Surgery,  
University of Toronto  
Chief, Division of Urology,  
Sunnybrook Health Sciences Centre

**Robert Nam**, MD, FRCS  
Head, Genitourinary Cancer Site Group  
Ajmera Family Chair in Urologic Oncology  
Odette Cancer Centre  
Sunnybrook Health Sciences Centre  
Associate Professor of Surgery  
University of Toronto

**China**

**Ningchen Li**, MD  
Professor and Vice Director  
Peking University Wujieping Urology Center  
No 9, Jinyuanzhuang Road, Shijingshan District,  
Beijing, China

**Egypt**

**Hassan Abol-Enein**, MD, PhD  
Professor of Urology  
Director of Urology & Nephrology Center  
Mansoura University  
Mansoura – Egypt

**England**

**Mark Emberton**, MD, FRCS, Urol  
Professor of Interventional Oncology, UCL  
Honorary Consultant Urological Surgeon UCH  
NHS Foundation Trust

**Italy**

**Maurizio Brausi**, MD  
Professor and Chairman of Urology  
Ausl Modena, Italy  
Chairman ESOU

**Japan**

**Fumiya Hongo**, MD, PhD  
Assitant Professor of Department of Urology  
Kyoto Prefectural University of Medicine  
Kyoto, Japan

**Yukio Homma**, MD, PhD  
Professor and Chair  
Department of Urology  
Graduate School of Medicine  
The University of Tokyo

**Keiji Inoue**, MD, PhD  
Department of Urology, Kochi Medical School  
Kohasu, Okoh-cho, Nankoku  
Kochi, Japan

**Tsuneharu Miki**, MD, PhD  
Professor and Chairman  
Department of Urology  
Department of Translational Cancer Drug Development  
Graduate School of Medical Science  
Kyoto Prefectural of University of Medicine  
Kawaramachi-Hirokoji  
Kyoto, Japan

**Masayuki Nakagawa**, MD, PhD  
Professor and Chairman  
Department of Urology  
Kagoshima University Faculty of Medicine  
Kagoshima, Japan

**Mototsugu Oya**, MD  
Professor and Chairman  
Department of Urology  
Keio University School of Medicine  
Japan

**Hiroyoshi Suzuki**, MD, PhD  
Professor of Urology  
Toho University Sakura Medical Center  
Chiba, Japan

**Yoshihiko Tomita**, MD, PhD  
Professor and Chairman  
Department of Urology  
Yamagata University Faculty of Medicine  
Iida-nish  
Yamagata, Japan

**Hirotsugu Uemura**, MD, PhD  
Professor and Chair  
Department of Urology  
Kinki University Faculty of Medicine  
377-2 Ohno-Higashi, Osaka-Sayama  
Osaka, Japan

**Korea**

**Jinsoo Chung**, MD, PhD  
Urology, Center for Prostate Cancer  
National Cancer Center  
Korea

**Singapore**

**Christopher Cheng**  
MBBS, FRCS, MMed, FAMS (Urology)  
Professor of Urology  
Singapore General Hospital

**Sweden**

**Jonas Hugosson**, MD  
Associate Professor  
Dept of Urology  
Sahlgrenska Academy  
Gothenburg University  
Sweden

**Switzerland**

**George Thalmann**, MD  
Professor of Urology  
Director and Chairman  
Department of Urology  
Bern University Hospital  
Anna Seiler Haus  
3010 Bern, Switzerland

**United States of America**

**Peter Albertsen**, MD, MS  
Professor and Chief, Division of Urology  
University of Connecticut Health Center

**Adam S. Kibel**, MD  
Chief of Urologic Surgery  
Brigham and Women's Hospital / Dana-Farber  
Cancer Institute  
Boston, Massachusetts

**John F. Ward**, MD, FACS  
Associate Professor of Surgery  
Department of Urology  
The University of Texas  
M. D. Anderson Cancer Center  
Houston, Texas

**Christopher G. Wood**, MD, FACS  
Douglas E. Johnson, MD Professorship  
Associate Professor & Deputy Chairman  
Department of Urology  
The University of Texas  
M. D. Anderson Cancer Center  
Houston, Texas

**Astellas**

**Edwina Baskin-Bey**, MD  
Director of Global Medical Science,  
Astellas Pharma Global Development  
Netherlands

**Immatics**

**Harpreet Singh**, PhD  
Chief Scientific Officer  
immatics biotechnologies  
Germany

The World Urological Oncology Federation  
extends its gratitude to the following Sponsors:

**Platinum**: Pfizer, Immatics

**Gold**: Astellas (Leading Light for Life)

**Silver**: Ferring Pharmaceuticals, Dendreon (Targeting Cancer, Transforming Lives®)



**World  
Urological  
Oncology  
Federation**



**WUOF 2012 Fukuoka  
Japan Conference**

**Sunday, September 30**

**New Technologies  
and New Therapies in  
Urologic Oncology**

